DK2969000T3 - Nye forbindelser - Google Patents

Nye forbindelser Download PDF

Info

Publication number
DK2969000T3
DK2969000T3 DK14711577.8T DK14711577T DK2969000T3 DK 2969000 T3 DK2969000 T3 DK 2969000T3 DK 14711577 T DK14711577 T DK 14711577T DK 2969000 T3 DK2969000 T3 DK 2969000T3
Authority
DK
Denmark
Prior art keywords
alkyl
pyridin
alkoxy
nr4ar4b
pyrrolo
Prior art date
Application number
DK14711577.8T
Other languages
English (en)
Inventor
Lee Patient
David Evans
Iain Simpson
Allison Powell
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Application granted granted Critical
Publication of DK2969000T3 publication Critical patent/DK2969000T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Claims (12)

1. Forbindelse af formel (I) eller et farmaceutisk acceptabelt salt, eller N-oxid deraf:
Hvor Y er valgt fra hydrogen, hydroxyl, -NH2, -NH-Ci-4-alkyl, -NH-halo-Ci-4-alkyl eller Ci-4-alkoxy; Z er valgt fra hydrogen, halogen, hydroxyl, cyano, Ci-4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy halo-Ci-4-alkoxy, CONH2, SO2NH2, -NH2, -NH-Ci-4-alkyl, -NH-halo-Ci-4-alkyl; R1 er en phenyl-ring, eller en 5- eller 6-leddet heteroaryl-ring, hvor hver ring eventuelt er substitueret med en eller flere substituenter valgt fra halogen, cyano, C1 4-alkyl, halo-Ci-4-alkyl, cyano-Ci-4-alkyl, Ci-4-alkoxy, halo-Ci-4-alkoxy, -NR4AR4B,-NR6C(0)0R5, -NR6C(0)R5, -NR6C(0)NR4AR4B, -C(O)NR4AR4B, -C(O)R5, -C(0)0R5, og -NR6S(0)2R5; W er en phenyl-ring eller en 5- eller 6-leddet heteroaryl-ring, hvor hver ring eventuelt er substitueret med en eller flere substituenter valgt fra halogen, cyano, C1 4-alkyl, halo-Ci-4-alkyl, cyano-Ci-4-alkyl, Ci-4-alkoxy, halo-Ci-4-alkoxy, -NR4AR4B,-NR6C(0)0R5, -NR6C(0)R5, -NR6C(0)NR4AR4B, -C(O)NR4AR4B, -C(O)R5, -C(0)0R5,-S02R5, -S02NR4AR4B og -NR6S(0)2R5; R2 er -B-Q-[R3]n eller -B-R3; hvor n = 1,2,3, eller 4 B er en binding, -O-, -NR5-, -C(O)- eller Ci-3-alkylen; Q er en mættet eller delvist umættet 3-7-leddet heterocyklisk eller C3-7-cy kloalky I-ring; når R2 er -B-0-[R3]n, R3 er valgt fra hydrogen, halogen, cyano, amino, hydroxyl, oxo, Ci-4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy, Ci-4alkoxy-Ci-4alkyl, hydroxy-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino-Ci-4-alkyl, di(Ci-4-alkyl)amino-Ci-4-alkyl, -NR4AR4B, -NR6C(0)0R5, -NR6C(0)R5, -NR6C(0)NR4AR4B,-C(O)NR4AR4B, -C(0)R5, -C(0)0R5, -NR6S(0)2R5, -S(0)2R5, Ci-4-alkyl-NR6C(0)0R5,-Ci-4-alkyl-NR6C(0)NR4AR4B, amino-Ci-4-alkoxy-Ci-4-alkyl-, (amino-Ci-4-alkyl)-amino-Ci-4-alkyl-, -Ci-4-alkyl-C(0) R5, -0C(0)R5, -Ci-4-alkyl-C(0)0R5, -Ci-4-alkyl-C(0)NR4AR4B, -Ci-4-alkyl-NR6C(0)NR4AR4B, 3-7-leddet heterocyklyl, C3-7-cykloalkyl, 3-7-leddet heterocyklyI-C1 -4-alkyl-, (3-7-leddet heterocyklyl-Ci-4-alkyl)-amino-Ci-4-alkyl-, phenyl-Ci-4-alkyl og 5- eller 6-leddet heteroaryl-Ci-4-alkyl, og hvor en hvilken som helst phenyl-eller heteroaryl-rest eventuelt er substitueret med en eller flere substituenter valgt fra halogen, cyano, C1 4-alkyl, halo-Ci-4-alkyl, C1-4-alkoxy, Ci-4alkoxy-Ci-4alkyl, hydroxy-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino-Ci-4-alkyl, di(Ci-4-alkyl)amino-Ci-4-alkyl, -NR4AR4B, -NR6C(0)0R5,-NR6C(O)R5, -NR6C(0)NR4AR4B, -C(0)NR4AR4B, -C(0)R5, -C(0)0R5, -NR6S(0)2R5; når R2 er -B-R3, R3 er valgt fra -NH2, Ci-4-alkoxy, Ci-4alkoxy-Ci-4alkyl, hydroxy-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino-Ci-4-alkyl, di( C1-4-alky I) am ino-C1-4-alky I, -NR4AR4B, -NR6C(0)0R5, -NR6C(0)R5,-NR6C(0)NR4AR4B, -C(O)NR4A1R4B, -C(0)R5, -NR6S(0)2R5, 3-7-leddet heterocyklyl-C1-4-alky I-, phenyl-Ci-4-alkyl og heteroaryl-Ci-4-alkyl, og hvor en hvilken som helst phenyl- eller heteroaryl-rest eventuelt er substitueret med en eller flere substituenter valgt fra halogen, cyano, C1-4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy, Ci-4alkoxy-Ci-4alkyl, hydroxy-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino-Ci-4-alkyl, di(Ci-4-alkyl)amino-Ci-4-alkyl, -NR4AR4B, -NR6C(0)0R5, -NR6C(0)R5,-NR6C(0)NR4AR4B, -C(O)NR4AR4B, -C(0)R5, -C(0)0R5, -NR6S(0)2R5, givet at når R2 er -B-R3, og B er en binding og R3 er -C(0)R5, så er R5 ikke hydrogen; R4A, R4B og R5 er hver uafhængigt valgt fra hydrogen, C1 4-alkyl, hydroxy-C1 4-alkyl, halo-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, C1-4- alkylam ino-Ci 4-alky I, di(Ci-4-alkyl)amino-Ci-4-alkyl eller Ci-4alkoxy-Ci-4alkyl, 3-7-leddet heterocyklyl-, 3-7-leddet heterocyklyl-Ci-4-alkyl-, C1-4-alkyl-NR6C(0)0R5, Ci-4-alkyl-NR6C(0)R5, (3-7-leddet heterocyklyl-Ci-4-alkyl)-amino-Ci 4-alkyl-, C3-7-cykloalkyl eller 5- eller 6-leddet heteroaryl-Ci-4-alkyl hvor alkyldelen af den 5- eller 6-leddede heteroaryl-Ci-4-alkylgruppe eventuelt er substitueret på et eller flere kulstofatomer med gruppe valgt fra halogen, Ci-4alkyl, eller C3-7-cykloalkyl, eller et af kulstofatomerne af den samme alkyldel er substitueret med to Ci-4alkyl-substituenter, der sammen med kulstofatomet til hvilket de er fastgjort danner en C3-7-cykloalkyI-ring, eller R4A og R4B sammen med nitrogenet til hvilket de er fastgjort danner en 4-7 leddet cyklisk aminogruppe eventuelt substitueret med en eller flere substituenter valgt fra: oxo, halogen, hydroxyl, cyano, C1 4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy, Ci-4alkoxy-Ci-4alkyl-, halo-Ci-4-alkoxy, -C(0)NR4AR4B, -CONH2, -SO2NH2, -NH2,-NHCi-4-alkyl, -NHhalo-Ci-4-alkyl, -C(0)R5, -C(0)0R5 eller -SO2R5, eller C3-7-cykloalkyl; medmindre på anden vis specificeret er den 3-7-leddede heterocyklyl, eller heterocyklyl-delen af den 3-7-leddede heterocyklyl-Ci 4-alkyl-, (3-7-leddet heterocyklyl-Ci-4-alkyl)-amino-Ci-4-alkyl-, eller (3-7-leddet heterocyklyl-Ci-4-alkyl)-C(O)- gruppe eventuelt substitueret med en eller flere substituenter valgt fra Ci-4-alkyl-,-C(0)0R5, -C(0)R5, -C(0)NR4AR4B, -NR4AR4B, - C1 -4- alky I- C(O) NR4AR4B, eller Ci-4alkoxy-Ci-4alkyl; og R4A1 er valgt fra C1 4-alkyl, hydroxy-Ci-4-alkyl, halo-Ci-4-alkyl, cyano-Ci-4-alkyl, amino-Ci-4-alkyl, Ci-4-alkylamino-Ci-4-alkyl, di(Ci-4-alkyl)amino-Ci-4-alkyl eller Ci-4alkoxy-Ci-4alkyl; eller R4A1 og R4B sammen med nitrogenet til hvilket de er fastgjort danner en 4-7 leddet cyklisk aminogruppe eventuelt substitueret med en eller flere substituenter valgt fra: oxo, halogen, hydroxyl, cyano, C1 4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy, Ci-4alkoxy-Ci-4alkyl-, halo-Ci-4-alkoxy, -CONH2, -SO2NH2, -NH2,-NHCi-4-alkyl, -NHhalo-Ci-4-alkyl, -C(0)R5, -C(0)0R5 eller -SO2R5, eller Cs-7-cykloalkyl. R6 er hydrogen eller C1 4-alkyl.
2. Forbindelse ifølge krav 1, hvor Yeller Z er H.
3. Forbindelse ifølge krav 1 eller krav 2, hvor R1 er en phenyl-ring eller en 6-leddet heteroaryl-ring, hvor hver ring eventuelt er substitueret med en eller flere substituenter valgt fra halogen, Ci 4-alkyl eller halo-Ci-4-alkyl.
4. Forbindelse ifølge et hvilket som helst af kravene 1 til 3, hvor W er en 5- eller 6-leddet heteroaryl-ring eventuelt substitueret med en eller flere substituenter valgt fra halogen, Ci 4-alkyl, halo-Ci-4-alkyl, Ci-4-alkoxy, halo-Ci-4-alkoxy eller -NR4AR4B.
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, hvor R2 er -Q-[R3]n
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor Q er en 7-leddet mættet eller delvist umættet 7-leddet heterocyklisk eller cykloalkyl-ring.
7. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor Q er en 5- eller 6-leddet mættet eller delvist umættet 5- eller 6-leddet heterocyklisk eller cykloalkyl-ring.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 7, hvor R3 er valgt fra hydrogen, C1-4-alkyl, Ci-4-alkoxy, halo-Ci 4-alkoxy, 3-7-leddet heterocyklyl, 3-7-leddet heterocyklyl-Ci-4-alkyl- eller -C(0)NR4AR4B.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 8, hvor Q er piperidinyl og R3 er -CONH2.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, hvor R2 er -B-R3, B er -Ci-3-alkylen-, og -R3 er -NR4AR4B, og R4A og R4B er hver uafhængigt valgt fra hydrogen og Ci-4-alkyl.
11. Forbindelse ifølge krav 1 valgt fra: 4-[2-(6-Aminopyridin-3-yl)-1-(4-chlorphenyl)-l H-pyrrolo[2,3-c]pyridin-3-yl] piperidin-1 -carboxamid; 4-[1-(4-Chlorphenyl)-2-(pyridin-3-yl)-1 H-pyrrolo[2,3-c] pyridin-3-y I] piperidin-1 -carboxamid; 4-[1-(4-Chlorphenyl)-2-(6-methoxypyridin-3-yl)-1 H-py r rolo[ 2,3-c] pyridin- 3- y I] piperidin-1 -carboxamid; 4- [1-(4-Chlorphenyl)-2-(2-methoxypyridin-4-yl)-l H-pyrrolo[2,3-c]pyridin- 3- y I] piperidin-1 -carboxamid; 4- [1 -(4-Chlorphenyl)-2-[2-(4-methylpiperazin-1 -y I) pyridin-4-y I] -1H-pyrrolo[2,3-c] pyridin-3-yl] piperidin-1 -carboxamid; 4-[1-(4-Chlorphenyl)-2-[6-(morpholin-4-yl)pyridin-3-yl]-1 H-pyrrolo[2,3- c] py ridin-3-y I] piperidin-1 -carboxamid; 4-[1 -(4-Chlorphenyl)-2-(pyrimidin-5-yl)-1 H-pyrrolo[2,3-c]pyridin-3-y I] piperidin-1 -carboxamid; 4-[1 - (4-Chlorpheny 1)-2-(1 H-pyrazol-3-yl)-1 H-pyrrolo[2,3-c] pyridin-3-y I] piperidin-1 -carboxamid; 4-[ 1 - (4-Chlorpheny 1)-2-(1 H-pyrazol-4-yl)-1 H-pyrrolo[2,3-c] py rid in-3-y I] piperidin-1 -carboxamid; 4-[1 -(4-Chlorpheny 1)-2-(1 - met hyl-1 H-pyrazol-4-yl)-1 H-pyrrolo[2,3-c] py ridin-3-y I] piperid in-1 - carboxamid; 4-[1 - (4-Chlorpheny 1)-2-(1 - methyl-1 H-pyrazol-5-yl)-1 H-pyrrolo[2,3-c] py ridin-3-y I] piperid in-1 - carboxamid; 4-[1 - (4-Chlorpheny 1)-2-(1 - methyl-1 H-imidazol-5-yl)-1 H-pyrrolo[2,3-c] py ridin-3-y I] piperid in-1 - carboxamid; 4-[1 - (4-Chlorpheny 1)-2-(1 H-pyrazol-1 - y I) -1 H-pyrrolo[2,3-c] pyridin-3-y I] piperidin-1 -carboxamid; 4-[1 - (4-Chlorpheny 1)-2-(1 H-imidazol-1 - y I) -1 H-pyrrolo[2,3-c] py rid in-3-y I] piperidin-1 -carboxamid; 4-[1 - (4-Chlorpheny I)-2-(1 H-1,2,3-triazol-1 -yl) -1 H-pyrrolo[2,3-c] pyridin-3-y I] piperidin-1 -carboxamid; 4-[1 - (4-Chlorpheny I)-2-(1 H-1,2,4-triazol-1 -y I) -1 H-pyrrolo[2,3-c] pyridin-3-y I] piperidin-1 -carboxamid; 4- [1 - (4-Chlorpheny l)-3-(piperidin-4-y 1)-1 H-pyrrolo[2,3-c] py ridin-2-y I] py ridin; 5- [1 - (4-Chlorpheny I)-3-(piperidin-4-y 1)-1 H-pyrrolo[2,3-c] py ridin-2-yl]pyridin-2-amin; {[1 - (4-Chlorpheny I) - 2-(pyridin-4-y 1)-1 H-pyrrolo[2,3-c]pyridin-3-yI] methyl} dimethylamin; {[1 -(4-Chlorphenyl)-2-(pyridin-3-yl)-1 H-pyrrolo[2,3-c]pyridin-3-yl] methyl} dimethylamin; og 4-[ 1 -(4-Chlorpheny I)-2-(2 H-1,2,3,4-tetrazol-5-yl)-1 H-pyrrolo[2,3-c]pyridin-3-yl]piperidin; og farmaceutisk acceptable salte deraf.
2. Farmaceutisk sammensætning omfattende en forbindelse ifølge et hvilket som helst af kravene 1 til 11, og en eller flere egnede excipienser.
3. Forbindelse ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i behandlingen af inflammation, en inflammatorisk sygdom, en immun- eller en autoimmun-lidelse, eller inhibition af tumorvækst.
4. Forbindelse til anvendelse ifølge krav 13, hvor inflammationen eller den inflammatoriske sygdom eller immun- eller autoimmunlidelsen er arthritis inklusiv rheumatoid arthritis, juvenil rheumatoid arthritis, osteoarthritis og psoriasisgigt, synovitis, vaskulitis, Sjogrens sygdom, en tilstand associeret med inflammation af tarmene inklusiv Crohns sygdom, ulcerativ colitis, inflammatorisk tarmsygdom og irritabel tyktarmssyndrom, aterosklerose, multipel sklerose, Alzheimers sygdom, vaskulær demens, Parkinsons sygdom, cerebral amyloid angiopati, cerebral autosomal dominant arteriopati med subkortikal infarkt og leukoencefalopati , en lungeinflammatorisk sygdom inklusiv astma, kronisk obstruktiv lungesygdom og akut lungesvigt-syndrom, en fibrotisk sygdom inklusiv idiopatisk lungefibrose, hjertefibrose, leverfibrose og systemisk sklerose også kendt som scleroderma, en inflammatorisk sygdom i huden inklusiv kontakteksem, atopisk eksem og psoriasis, en inflammatorisk sygdom i øjet inklusiv aldersrelateret makulær degeneration, uveitis og diabetisk retinopati, systemisk inflammatorisk responssyndrom, sepsis, en inflammatorisk og/eller autoimmun tilstand af leveren inklusiv autoimmun hepatitis, primær biliser cirrose, alkoholisk leversygdom, skleroserende cholangit, og autoimmun cholangit, type I- eller ll-diabetes og/eller komplikationerne deraf, kronisk hjertesvigt, hjertesvigt, en iskæmisk sygdom inklusiv slagtilfælde og iskæmi-reperfusionsskade eller myokardieinfarkt og/eller komplikationerne deraf, eller epilepsi.
15. Forbindelse til anvendelse ifølge krav 13 til behandling af en sygdom valgt fra rheumatoid arthritis, osteoarthritis, leverfibrose, kronisk obstruktiv lungesygdom, multipel sklerose, Sjogrens sygdom, Alzheimers sygdom, Parkinsons sygdom, inflammatorisk tarmsygdom og vaskulær demens.
DK14711577.8T 2013-03-13 2014-03-13 Nye forbindelser DK2969000T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1304527.3A GB201304527D0 (en) 2013-03-13 2013-03-13 New compounds
PCT/GB2014/050764 WO2014140591A1 (en) 2013-03-13 2014-03-13 New compounds

Publications (1)

Publication Number Publication Date
DK2969000T3 true DK2969000T3 (da) 2018-03-26

Family

ID=48189849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14711577.8T DK2969000T3 (da) 2013-03-13 2014-03-13 Nye forbindelser

Country Status (10)

Country Link
US (1) US9580415B2 (da)
EP (1) EP2969000B1 (da)
JP (1) JP6285470B2 (da)
AU (1) AU2014229762B2 (da)
CA (1) CA2902116C (da)
DK (1) DK2969000T3 (da)
ES (1) ES2663448T3 (da)
GB (1) GB201304527D0 (da)
HK (1) HK1219071A1 (da)
WO (1) WO2014140591A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
GB201416446D0 (en) 2014-09-17 2014-10-29 Proximagen Ltd New enzyme inhibitor compounds
GB201416444D0 (en) * 2014-09-17 2014-10-29 Proximagen Ltd New compounds
TW201630907A (zh) * 2014-12-22 2016-09-01 必治妥美雅史谷比公司 ＴＧＦβＲ拮抗劑
CA3007768A1 (en) 2015-12-07 2017-06-15 Benevolentai Cambridge Limited Vap-1 inhibitors for treating pain
EP4125968A4 (en) * 2020-03-25 2024-04-10 Terns Inc TREATMENT OF RESPIRATORY DISORDERS
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002214505A1 (en) 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
US6982286B2 (en) 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
JP2007501802A (ja) 2003-08-08 2007-02-01 ラ ホヤ ファーマシューティカル カンパニー 疾患の処置に有用な、セミカルバジド感受性アミンオキシダーゼ（ｓｓａｏ）およびｖａｐ−１媒介性接着のインヒビター
BRPI0414136A (pt) * 2003-09-04 2006-10-31 Aventis Pharma Inc indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
WO2007120528A2 (en) 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
CA2737527C (en) 2008-09-16 2015-12-29 Proximagen Limited 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds useful as inhibitors of ssao activity
EP2328895B1 (en) 2008-09-16 2013-03-27 Proximagen Limited Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO
JP2012510983A (ja) * 2008-12-04 2012-05-17 プロキシマジェン エルティーディー イミダゾピリジン化合物
EP2417133A1 (en) 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Compounds and methods for antiviral treatment
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
JP5796130B2 (ja) 2011-09-14 2015-10-21 プロクシマゲン リミテッド 新規な酵素阻害剤化合物
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201404498D0 (en) 2014-03-13 2014-04-30 Proximagen Ltd New compounds
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy

Also Published As

Publication number Publication date
ES2663448T3 (es) 2018-04-12
EP2969000A1 (en) 2016-01-20
CA2902116A1 (en) 2014-09-18
JP2016510800A (ja) 2016-04-11
US20160024080A1 (en) 2016-01-28
CA2902116C (en) 2021-06-15
US9580415B2 (en) 2017-02-28
WO2014140591A1 (en) 2014-09-18
HK1219071A1 (zh) 2017-03-24
GB201304527D0 (en) 2013-04-24
AU2014229762A1 (en) 2015-09-10
JP6285470B2 (ja) 2018-02-28
AU2014229762B2 (en) 2017-12-21
EP2969000B1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
DK2969000T3 (da) Nye forbindelser
AU2014229763B2 (en) Imidazo[4,5-C]pyridine and pyrrolo[2,3-C]pyridine derivatives as SSAO inhibitors
US11945812B2 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
DK2547677T3 (da) Hæmmere af semicarbazid-sensitiv aminoxidase
AU2008292390B2 (en) Polycyclic compound
US20220380382A1 (en) New macrocyclic compounds and derivatives as egfr inhibitors
EP2755975A1 (en) New enzyme inhibitor compounds
EP2755974A1 (en) New enzyme inhibitor compounds
US20150258101A1 (en) New compounds
BR112017025356B1 (pt) Composto, composição farmacêutica, e, uso para a fabricação de um medicamento